Medicine for treating cancer and method for treating cancer

Abstract

An object of the present invention is to reveal a role of a stem cell control factor including Matrin-3 in cancer exhibiting neural differentiation including small cell lung cancer, and develop a medicine useful for treating cancer and the like based on the role. Among cancers having the cancer stem cell controlling mechanism, in cancer exhibiting the differentiation potency, the peculiar balance where both of expression of a stem cell maintenance factor and expression of a differentiation promoting factor are higher as compared with normal cells is retained. Additionally, in undifferentiated cancer, the peculiar balance where expression of a stem cell maintenance factor is higher as compared with normal cells is retained. In cancer in which the cancer stem cell controlling mechanism exists, these peculiar balances of a stem cell control factor different from the balance of normal cells exist. In the medicine for treating cancer and the method for treating cancer of the present invention, proliferativeness of cancer is suppressed by breaking down this balance of a stem cell control factor.

1 . A medicine for treating cancer, the medicine suppressing proliferation of cancer cells by breaking down a cancer stem cell controlling mechanism, in cancer exhibiting differentiation potency and cancer having undifferentiated property, wherein
 the breaking down of the cancer stem cell controlling mechanism is performed by at least one of suppressing an expression amount of a stem cell control factor, suppressing an expression amount of a phosphorylated stem cell control factor, and inhibiting phosphorylation of the stem cell control factor; and furthermore,   the stem cell control factor is at least one of INI1 and Matrin-3.   
     
     
         2 - 4 . (canceled) 
     
     
         5 . The medicine for treating cancer according to  claim 1 , wherein suppression of the expression amount of the stem cell control factor is performed by a medicine containing an anti-stem cell control factor antibody as an active ingredient. 
     
     
         6 . The medicine for treating cancer according to  claim 1 , wherein suppression of the expression amount of the phosphorylated stem cell control factor is performed by a medicine containing an anti-phosphorylated stem cell control factor antibody as an active ingredient. 
     
     
         7 . The medicine for treating cancer according to  claim 1 , wherein suppression of the expression amount of the stem cell control factor is performed by a medicine containing a siRNA to the stem cell control factor as an active ingredient. 
     
     
         8 . The medicine for treating cancer according to  claim 7 , wherein the siRNA has a sequence described in SEQ ID Nos.: 1 to 6. 
     
     
         9 . (canceled) 
     
     
         10 . The medicine for treating cancer according to  claim 1 , wherein the cancer exhibiting the differentiation potency, and the cancer having undifferentiated property are neuroendocrine tumor. 
     
     
         11 . The medicine for treating cancer according to  claim 1 , wherein the cancer exhibiting the differentiation potency, and the cancer having undifferentiated property are selected from any of small cell lung cancer, leukemia, breast cancer, large intestine cancer, stomach cancer, rectum cancer, skin cancer, prostate cancer, ovary cancer, uterine body cancer, pancreas cancer, osteosarcoma, and neuroblastoma cancer. 
     
     
         12 - 14 . (canceled)